Skip to main content

Open Access Interleukin 8: An Autocrine Growth Factor for Human Ovarian Cancer

Download Article:
We determined whether interleukin-8 (IL-8) plays a direct role in the progressive growth of ovarian cancer cells by isolating high- and low-IL-8-producing clones from the parental Hey-A8 human ovarian cancer cell line and compared their proliferative activity and tumorigenicity in nude mice. The effect of exogenous IL-8 and mouse antihuman IL-8 neutralizing antibody on ovarian cancer cell proliferation was investigated. Finally, we studied the modulation of IL-8 production in ovarian cancer cells by sense and antisense IL-8 expression vector transfection and its effect on proliferation. The Hey-A8(H) clone was selected for its overexpression of IL-8. It has a significantly higher proliferation rate than the low-IL-8-producing clone, Hey-A8(L). Recombinant IL-8 (50 ng/ml) caused a significant increase in proliferation of Hey-A8(L) clones, and 10 μg/ml neutralizing antibody against IL-8 significantly decreased proliferative activity of both Hey-A8(H) and Hey-A8(L) clones. Enforced IL-8 expression by IL-8 expression vector transfection in Hey-A8(L) clones significantly increased tumor cell proliferation, microvessel density, and hence, tumorigenicity. We conclude that IL-8 has a direct and indirect growth-potentiating activity in human ovarian cancer cells.

Keywords: Autocrine growth factor;; Key words: Interleukin-8

Document Type: Research Article

Affiliations: Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030

Publication date: 01 February 2001

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

    From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.

  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content